CR20110599A - Composiciones farmacéuticamente activas que comprenden moduladores de estrés oxidativo (osm), nuevas entidades químicas, composiciones y usos - Google Patents
Composiciones farmacéuticamente activas que comprenden moduladores de estrés oxidativo (osm), nuevas entidades químicas, composiciones y usosInfo
- Publication number
- CR20110599A CR20110599A CR20110599A CR20110599A CR20110599A CR 20110599 A CR20110599 A CR 20110599A CR 20110599 A CR20110599 A CR 20110599A CR 20110599 A CR20110599 A CR 20110599A CR 20110599 A CR20110599 A CR 20110599A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compositions
- osm
- pharmaceutically active
- oxidative stress
- chemical entities
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 2
- 150000005829 chemical entities Chemical class 0.000 title 1
- 230000036542 oxidative stress Effects 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describen composiciones farmacéuticas y medicamentos, y métodos para utilizar dichas composiciones farmacéuticas y medicamentos para el tratamiento de inflamación y cáncer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17055509P | 2009-04-17 | 2009-04-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20110599A true CR20110599A (es) | 2012-02-09 |
Family
ID=42983172
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20110599A CR20110599A (es) | 2009-04-17 | 2011-11-15 | Composiciones farmacéuticamente activas que comprenden moduladores de estrés oxidativo (osm), nuevas entidades químicas, composiciones y usos |
Country Status (16)
Country | Link |
---|---|
US (1) | US20100297262A1 (es) |
EP (1) | EP2419095A4 (es) |
JP (2) | JP2012524074A (es) |
KR (1) | KR20120008056A (es) |
CN (1) | CN102438615A (es) |
AP (1) | AP2011005974A0 (es) |
AU (1) | AU2010236203A1 (es) |
BR (1) | BRPI1014978A2 (es) |
CA (1) | CA2756820A1 (es) |
CL (1) | CL2011002595A1 (es) |
CR (1) | CR20110599A (es) |
IL (1) | IL215847A0 (es) |
MX (1) | MX2011010956A (es) |
SG (1) | SG175251A1 (es) |
WO (1) | WO2010121177A2 (es) |
ZA (1) | ZA201108369B (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8853277B2 (en) | 2009-11-30 | 2014-10-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nitroxide therapy for the treatment of von Hippel—Lindau disease (VHL) and renal clear cell carcinoma (RCC) |
US8816071B2 (en) | 2011-12-02 | 2014-08-26 | First Tech International Limited | Tocotrienol derivatives and associated methods |
ES2692726T3 (es) * | 2012-12-20 | 2018-12-04 | General Electric Company | Formulaciones para la estabilización de ácidos nucleicos en sustratos sólidos |
PT2989110T (pt) * | 2013-04-24 | 2018-11-15 | Jira Neuzil | Derivados de tamoxifeno para o tratamento de doenças neoplásicas, especialmente com nível elevado de proteína her2 |
US11161862B2 (en) | 2017-04-20 | 2021-11-02 | Oxford University Innovation Limited | Phosphonium-ion tethered tetracycline drugs for treatment of cancer |
EP3612540A1 (en) | 2017-04-20 | 2020-02-26 | Rising Tide Foundation | Triphenylphosphonium-tethered tetracycyclines for use in treating cancer |
CA3060509A1 (en) | 2017-04-21 | 2018-10-25 | Federica Sotgia | Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy |
CA3060510A1 (en) | 2017-04-21 | 2018-10-25 | Lunella Biotech, Inc. | Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs) |
EP3624840A4 (en) | 2017-05-19 | 2021-03-10 | Lunella Biotech, Inc. | ANTIMITOSCINE: TARGETED INHIBITORS OF MITOCHONDRIAL BIOGENESIS TO DESCRIBE CANCER STEM CELLS |
MX2019014806A (es) | 2017-06-26 | 2020-02-10 | Lunella Biotech Inc | Mitocetoscinas: agentes terapeuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en celulas cancerosas. |
US11541120B2 (en) * | 2017-12-05 | 2023-01-03 | Anthos Partners, Lp | Phosphonium-based ionic drug conjugates |
WO2019185939A1 (en) * | 2018-03-29 | 2019-10-03 | Dsm Ip Assets B.V. | Use of twin-chromanols as antioxidants in oil |
PE20211495A1 (es) * | 2018-03-29 | 2021-08-11 | Dsm Ip Assets Bv | Uso novedoso de cromanoles gemelos |
WO2021125800A1 (ko) * | 2019-12-16 | 2021-06-24 | 울산과학기술원 | 신생혈관형성인자의 억제를 위한 화합물 및 그 용도 |
CN110980915B (zh) * | 2019-12-23 | 2022-08-02 | 解冰 | 一种纳米氧自由基水在抗癌药物中的应用 |
CN112133369B (zh) * | 2020-08-26 | 2023-09-22 | 吴安华 | 基于活性氧评估肿瘤患者预后性的系统以及药物敏感性评价与改善方法 |
WO2022265178A1 (ko) * | 2021-06-15 | 2022-12-22 | 주식회사 스마틴바이오 | Trap1 억제제 및 이의 용도 |
CN117442601B (zh) * | 2023-10-31 | 2024-05-28 | 上海市东方医院(同济大学附属东方医院) | 一种磷酸酶抑制剂类似物BX-金属NPs及其制备方法和应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0669132A1 (en) * | 1994-02-23 | 1995-08-30 | van der Kraaij, Antonius Marinus Maria | Pharmaceutical composition of vitamin E and acetylsalicylate for treatment and prevention of atherosclerosis |
DE69515842T2 (de) * | 1995-04-07 | 2000-11-02 | Sanofi Synthelabo | Kombinationspräparat von Acetylsalicylat von Lysin, Vitamine E und Beta-Karotin |
US20080275005A1 (en) * | 1998-11-25 | 2008-11-06 | Murphy Michael P | Mitochondrially targeted antioxidants |
US20030091553A1 (en) * | 2001-10-19 | 2003-05-15 | Gehlsen Kurt R. | Use of histamine to treat liver disease |
US7148211B2 (en) * | 2002-09-18 | 2006-12-12 | Genzyme Corporation | Formulation for lipophilic agents |
US20040102421A1 (en) * | 2002-11-21 | 2004-05-27 | Children's Hospital Research Center At Oakland | Tocopherol and tocotrienol anti-inflammatory medicaments |
US7326734B2 (en) * | 2003-04-01 | 2008-02-05 | The Regents Of The University Of California | Treatment of bladder and urinary tract cancers |
CN101856348A (zh) * | 2003-08-29 | 2010-10-13 | 斯隆-凯特林癌症研究所 | 联合治疗癌症的方法 |
WO2006005759A2 (en) * | 2004-07-13 | 2006-01-19 | Oridis Biomed Forschungs- Und Entwicklungs Gmbh | Mitochondrially targeted antioxidants in the treatment of liver diseases and epithelial cancers |
EP1719508A1 (en) * | 2005-05-06 | 2006-11-08 | Yih-Lin Chung | Use of histone deacetylase inhibitors for the prevention or treatment of joint destruction |
US20070161609A1 (en) * | 2006-01-10 | 2007-07-12 | Charles Buck | Use of mitochondrially targeted antioxidant in treatment and prevention of drug-induced liver disease |
US20080032940A1 (en) * | 2006-08-07 | 2008-02-07 | Balaraman Kalyanaraman | Methods for reducing anthracycline-induced toxicity |
JP2010509370A (ja) * | 2006-11-10 | 2010-03-25 | シンダックス ファーマシューティカルズ,インク. | 癌の治療用のERα+リガンドとヒストンデアセチラーゼ阻害剤との組み合わせ |
-
2010
- 2010-04-16 BR BRPI1014978A patent/BRPI1014978A2/pt not_active IP Right Cessation
- 2010-04-16 JP JP2012505976A patent/JP2012524074A/ja active Pending
- 2010-04-16 AP AP2011005974A patent/AP2011005974A0/xx unknown
- 2010-04-16 US US12/762,274 patent/US20100297262A1/en not_active Abandoned
- 2010-04-16 KR KR1020117027363A patent/KR20120008056A/ko not_active Application Discontinuation
- 2010-04-16 CA CA2756820A patent/CA2756820A1/en not_active Abandoned
- 2010-04-16 AU AU2010236203A patent/AU2010236203A1/en not_active Abandoned
- 2010-04-16 WO PCT/US2010/031455 patent/WO2010121177A2/en active Application Filing
- 2010-04-16 MX MX2011010956A patent/MX2011010956A/es not_active Application Discontinuation
- 2010-04-16 SG SG2011075751A patent/SG175251A1/en unknown
- 2010-04-16 CN CN2010800183159A patent/CN102438615A/zh active Pending
- 2010-04-16 EP EP10765289A patent/EP2419095A4/en not_active Withdrawn
-
2011
- 2011-10-17 CL CL2011002595A patent/CL2011002595A1/es unknown
- 2011-10-23 IL IL215847A patent/IL215847A0/en unknown
- 2011-11-15 ZA ZA2011/08369A patent/ZA201108369B/en unknown
- 2011-11-15 CR CR20110599A patent/CR20110599A/es unknown
-
2015
- 2015-05-27 JP JP2015107975A patent/JP2015172066A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
ZA201108369B (en) | 2013-02-27 |
KR20120008056A (ko) | 2012-01-25 |
WO2010121177A3 (en) | 2011-03-31 |
JP2012524074A (ja) | 2012-10-11 |
CA2756820A1 (en) | 2010-10-21 |
EP2419095A2 (en) | 2012-02-22 |
JP2015172066A (ja) | 2015-10-01 |
IL215847A0 (en) | 2012-01-31 |
BRPI1014978A2 (pt) | 2019-07-02 |
MX2011010956A (es) | 2012-01-27 |
EP2419095A4 (en) | 2012-12-05 |
WO2010121177A2 (en) | 2010-10-21 |
CN102438615A (zh) | 2012-05-02 |
US20100297262A1 (en) | 2010-11-25 |
SG175251A1 (en) | 2011-11-28 |
AU2010236203A1 (en) | 2011-10-13 |
AP2011005974A0 (en) | 2011-12-31 |
CL2011002595A1 (es) | 2013-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20110599A (es) | Composiciones farmacéuticamente activas que comprenden moduladores de estrés oxidativo (osm), nuevas entidades químicas, composiciones y usos | |
ECSP23004573A (es) | Compuestos y composiciones como inhibidores de cinasa de proteina | |
CL2012003415A1 (es) | Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer . | |
CL2012001971A1 (es) | Compuestos derivados de 1-piperazinil-3-piridin-carboxilato, como bloqueadores de los canales de sodio dependientes de voltaje; composicion farmaceutica; y su uso para el tratamiento de enfermedades respiratorias o del tracto respiratorio tal como asma, epoc, tos, silicosis, entre otras. | |
CL2014000956A1 (es) | Compuestos derivados de (4-fenilimidazol-2-il)etilamina, como moduladores de canal de sodio; composicion farmaceutica que los comprende; y su uso en el tratamiento del dolor. | |
ECSP109934A (es) | Compuesto - 946 | |
NI201300041A (es) | Antagonistas de mdm2 de espiro-oxindol | |
CO7101245A2 (es) | Compuestos de benzaldehído sustituidos y métodos para su uso en incrementar la oxigenación del tejido | |
CL2012003226A1 (es) | Compuestos derivados de 5-fluoro-1h-pirazolopiridina ; procedimiento de preparacion de estos; composicion framaceutica que los comprende; y su uso en el tratamiento de enfermedades cardiovasculares, sexuales y metabolicas. | |
CL2013000018A1 (es) | Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros. | |
CL2013000063A1 (es) | Un método para tratar a un sujeto que comprende administrar n-etil-n-fenil1,2-dihidroxi-4-hodroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida opcionalmente deuterada, para el tratamiento de una enfermedad autoinmunitaria; una mezcla de los mismos; composición farmaceutica y su proceso de preparacion. | |
CL2011003350A1 (es) | Compuestos derivados de heterociclo nitrogenados, moduladores pkm2; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer. | |
CL2012002944A1 (es) | Compuestos derivados de amino-pirimidinas; composiciones farmacéuticas que los comprenden; y su uso para el tratamiento de una enfermedad afección seleccionada de trastornos neuromusculares, esclerosis lateral amiotrófica, miastenia grave, entre otras. | |
CL2012002945A1 (es) | Compuestos derivados de amino-piridazinas; composiciones farmacéuticas que los comprenden; y su uso para el tratamiento de una enfermedad afección seleccionada de trastornos neuromusculares, esclerosis lateral amiotrófica, miastenia grave, entre otras. | |
CL2012003281A1 (es) | Uso de compuestos específicos estimuladores y/o activadores de sgc; formulacion farmaceutica que comprende dichos compuestos; kit que comprende los compuestos, y uso para la prevencion y/o tratamiento de la esclerosis sistematica. | |
CR11455A (es) | Compuestos nuevos de hidrocarbono ciclico para el tratamiento de enfermedades | |
CL2012001714A1 (es) | Compuestos derivados de pirrol[3.4-b]piridin-5-ona, inhibidores de pi3k; composicion farmaceutica que los comprende; y uso para el tratamiento de enfermedades tales como alzheimer, epilepsia, esclerosis multiple, parkinson, entre otras. | |
BR112015018087A8 (pt) | composto, composição farmacêutica e uso | |
EA201200937A1 (ru) | Твердая лекарственная форма тикагрелора | |
NI201000044A (es) | Bromhidrato de bupropión y aplicaciones terapéuticas | |
SV2010003559A (es) | Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos | |
ECSP12011585A (es) | Compuestos y composiciones para eltratamiento de enfermedades parasitarias | |
CR20140144A (es) | Derivados de estra-1,3,5 (10), 16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos | |
BR112014027981A2 (pt) | compostos do tipo fumagilol e métodos de produção e utilização dos mesmos | |
NI201000015A (es) | Bromhidrato de bupropión y aplicaciones terapéuticas |